echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Ha Medical University invented molecular probes to predict the effect of cancer-targeted treatment

    Ha Medical University invented molecular probes to predict the effect of cancer-targeted treatment

    • Last Update: 2020-12-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    , a paper published in
    , a sub-issue of Science, reported that the Shen Baozhong team at Harbin Medical University in China had successfully constructed a molecular probe for PET (positive electron emission computer fault imaging) imaging - 18F-MPG. Through this probe, it can identify lung cancer EGFR (skin growth factor subject) type in real time, dynamically and accurately, guide the decision-making of clinical targeted drug therapy, and predict and evaluate the effect of cancer-targeted treatment.The
    team developed a molecular imaging probe 18F-MPG that binds to specific proteins in lung cancer cells, and using the probe, the researchers were able to capture the position and number of probe bindings in a live state through PET imaging to determine the EGFR segmentation status and dynamic changes of lung cancer, and uninscionablely screened patients who could be targeted by EGFR molecules.
    " molecular probe screened targeted treatment sensitive patient group after treatment of the average tumor progression survival time is 348 days, while the unfiltered patient group tumor progression survival time is 183 days. Professor Shen Baozhong said the data showed that the probe-sensitive lung cancer patient population has better treatment results, longer tumor progressive survival and better prognostication, probe can be used to target the prediction of cancer treatment effect.
    If intracranial metastasis occurs in lung cancer patients, the current conventional PET imaging judgment is insensitive, while the new probe 18F-MPG is not ingested in normal brain tissue and is highly ingested in metastasis tumors with EGFR mutations, which can enable accurate diagnosis of intracranial metastasis." Professor Shen Baozhong said that in terms of safety, none of the subjects had a side effect. (Source: Science and Technology Daily Zhang Jiaxing)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.